{"id":3568,"date":"2020-11-19T15:22:44","date_gmt":"2020-11-19T15:22:44","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3568"},"modified":"2020-11-19T15:25:07","modified_gmt":"2020-11-19T15:25:07","slug":"nouvelle-publication-une-nouvelle-classe-de-molecules-ciblant-la-famille-des-proteines-neet","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/nouvelle-publication-une-nouvelle-classe-de-molecules-ciblant-la-famille-des-proteines-neet\/","title":{"rendered":"Nouvelle publication :  une nouvelle classe de mol\u00e9cules ciblant la famille des prot\u00e9ines NEET"},"content":{"rendered":"<p>ENYO est fier de partager sa derni\u00e8re publication d\u00e9crivant le le d\u00e9veloppement de MITO-C (l&#8217;un des compos\u00e9s de son programme EYP002) une nouvelle classe de mol\u00e9cules ciblant la famille des prot\u00e9ines NEET. Ce travail est le fruit d&#8217;une collaboration internationale et a \u00e9t\u00e9 dirig\u00e9 par Etienne Morel (INEM, Paris, France) et Beno\u00eet de Chassey (ENYO Pharma, Lyon, France) gr\u00e2ce \u00e0 un financement d&#8217;ENYO Pharma. Il montre que MITO-C module la morphogen\u00e8se mitochondriale et stabilise les sites de contact entre le r\u00e9ticulum endoplasmique et la mitochondrie. Ce travail fondamental ouvre la voie \u00e0 des indications th\u00e9rapeutiques qui vont au-del\u00e0 des maladies infectieuses comme les maladies m\u00e9taboliques ou neurod\u00e9g\u00e9n\u00e9ratives. <a href=\"http:\/\/www.enyopharma.com\/fr\/technologie\/publications\/\">Acc\u00e8s \u00e0 la publication<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ENYO est fier de partager sa derni\u00e8re publication d\u00e9crivant le le d\u00e9veloppement de MITO-C (l&#8217;un des compos\u00e9s de son programme EYP002) une nouvelle classe de mol\u00e9cules ciblant la famille des prot\u00e9ines NEET. Ce travail est le fruit d&#8217;une collaboration internationale et a \u00e9t\u00e9 dirig\u00e9 par Etienne Morel (INEM, Paris, France) et Beno\u00eet de Chassey (ENYO Pharma, Lyon, France) gr\u00e2ce \u00e0 un financement d&#8217;ENYO Pharma. Il montre que MITO-C module la morphogen\u00e8se mitochondriale et stabilise les sites de contact entre le r\u00e9ticulum endoplasmique et la mitochondrie.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/nouvelle-publication-une-nouvelle-classe-de-molecules-ciblant-la-famille-des-proteines-neet\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-3568","post","type-post","status-publish","format-standard","hentry","category-latest-news-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/latest-news-fr\/\" rel=\"category tag\">Br\u00e8ves<\/a>","rttpg_excerpt":"ENYO est fier de partager sa derni\u00e8re publication d\u00e9crivant le le d\u00e9veloppement de MITO-C (l&#8217;un des compos\u00e9s de son programme EYP002) une nouvelle classe de mol\u00e9cules ciblant la famille des prot\u00e9ines NEET. Ce travail est le fruit d&#8217;une collaboration internationale et a \u00e9t\u00e9 dirig\u00e9 par Etienne Morel (INEM, Paris, France) et Beno\u00eet de Chassey (ENYO&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3568"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3568\/revisions"}],"predecessor-version":[{"id":3574,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3568\/revisions\/3574"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}